NDAINJECTIONINJECTABLE
Approved
Dec 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
INTRALIPID 30% (i. v. fat emulsion) by Fresenius Kabi is clinical pharmacology intralipid is metabolized and utilized as a source of energy causing an increase in heat production, decrease in respiratory quotient and increase in oxygen consumption. First approved in 1993.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INTRALIPID 30% is an intravenous fat emulsion used to provide essential fatty acids and energy in parenteral nutrition settings. It is metabolized as an energy source while preventing essential fatty acid deficiency (EFAD) and correcting EFAD syndrome manifestations. The product mimics natural chylomicron clearance mechanisms.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), suggesting small brand teams and focus on cost containment and customer retention rather than expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY Intralipid is metabolized and utilized as a source of energy causing an increase in heat production, decrease in respiratory quotient and increase in oxygen consumption. The infused fat particles are cleared from the blood stream in a manner thought to be comparable to the…
Pharmacologic Class:
Lipid Emulsion
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Roles linked to INTRALIPID 30% are minimal (0 current openings), reflecting the product's mature, commoditized status. Career advancement on this product centers on hospital relationship management, cost optimization, and regulatory compliance rather than revenue growth or innovation.
Account Manager
Worked on INTRALIPID 30% at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.